Search Medical Condition
Please enter condition
Please choose location
 

Guro-gu, Korea, Republic of Clinical Trials

A listing of Guro-gu, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (756) clinical trials

Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-DFU in Paitents With Diabetic Foot Ulcers

ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in ...

Phase

0.0 miles

Learn More »

Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer

The purpose of this study is to evaluate the clinical benefit and safety of Apatinib plus Best Supportive Care in comparison to Placebo plus Best Supportive Care in patients with advanced or metastatic gastric cancer

Phase

0.0 miles

Learn More »

Prevalence of Coronary Artery Disease in the Siblings of Premature Coronary Heart Disease

The aim of this prospective study is to investigate the prevalence of coronary artery disease using computed tomography with family history of premature coronary heart disease

Phase N/A

1.43 miles

Learn More »

Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)

The purpose of this study is to determine whether norepinephrine gene polymorphism affect to treatment response in ADHD

Phase

1.77 miles

Learn More »

Intravitreal Vascular Endothelial Growth Factor Trap-eye for Submacular Hemorrhage

The prognosis of exudative age-related macular degeneration (AMD) accompanied by submacular hemorrhage is generally poor. Although anti-vascular endothelial growth factor (VEGF) has been demonstrated excellent efficacy in the treatment of exudative AMD, eyes with submacular hemorrhage were excluded from the previous well-known clinical trials. The exclusion of these patients may ...

Phase

1.86 miles

Learn More »

Post Marketing Surveillance Study For Sayana

Post Marketing Surveillance required by Korea MFDS regulation. Select among patients who randomly visit the site who meet the inclusion/exclusion criteria.

Phase N/A

2.68 miles

Learn More »

Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).

Patients will be randomized in a 1:1 to receive treatment with durvalumab + tremelimumab combination therapy or SoC therapy. The primary objective of this study is to assess the efficacy of combination treatment compared with SoC in terms of Overall Survival (OS) in patients.

Phase

2.91 miles

Learn More »

A Registry of Participants With Prostate Cancer in Asia

This is a multicenter (when more than one hospital or medical school team work on a medical research study), prospective (observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group), ...

Phase N/A

2.91 miles

Learn More »

Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

Phase

2.91 miles

Learn More »

A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination treatment of ibrutinib with everolimus, paclitaxel, docetaxel, or cetuximab in selected advanced gastrointestinal and genitourinary tumors.

Phase

2.91 miles

Learn More »